Research graph
References from CLDN18.2 targeting enhances chemotherapy sensitivity in pancreatic cancer cells and lung cancer organoids. Local targets link to admitted publications; unresolved targets remain external evidence.
Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development
10.1158/1078-0432.ccr-08-1547 · 2008 · External reference
Claudin 18.2 as a novel therapeutic target
10.1038/s41571-024-00874-2 · 2024 · External reference
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
10.1016/s0140-6736(23)00620-7 · 2023 · External reference
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
10.1038/s41591-023-02465-7 · 2023 · External reference
Ferroptosis: an iron-dependent form of nonapoptotic cell death
10.1016/j.cell.2012.03.042 · 2012 · External reference
Cysteine depletion induces pancreatic tumor ferroptosis in mice
10.1126/science.aaw9872 · 2020 · External reference
FAM120A deficiency improves resistance to cisplatin in gastric cancer by promoting ferroptosis
10.1038/s42003-024-06097-6 · 2024 · External reference
Assessment of lipid peroxidation in irradiated cells
10.1016/bs.mcb.2022.05.003 · 2022 · External reference
Protocol for detection of ferroptosis in cultured cells
10.1016/j.xpro.2023.102457 · 2023 · External reference
CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors
2024 · External reference
LEF1 suppresses ferroptosis in colorectal cancer cells by targeted promotion of SLC7A11 transcription
10.1096/fj.202502018r · 2025 · External reference
Loss of tight junction protein Claudin 18 promotes progressive neoplasia development in mouse stomach
10.1053/j.gastro.2018.08.041 · 2018 · External reference
Expression and prognostic analysis of CLDN18 and Claudin18.2 in lung adenocarcinoma
10.1016/j.prp.2022.154068 · 2022 · External reference
Assessment of lipid peroxidation in irradiated cells
10.1016/bs.mcb.2022.05.003 · ExternalCitation · doi-reference
Ferroptosis: an iron-dependent form of nonapoptotic cell death
10.1016/j.cell.2012.03.042 · ExternalCitation · doi-reference
Expression and prognostic analysis of CLDN18 and Claudin18.2 in lung adenocarcinoma
10.1016/j.prp.2022.154068 · ExternalCitation · doi-reference
Protocol for detection of ferroptosis in cultured cells
10.1016/j.xpro.2023.102457 · ExternalCitation · doi-reference
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
10.1016/s0140-6736(23)00620-7 · ExternalCitation · doi-reference
Claudin 18.2 as a novel therapeutic target
10.1038/s41571-024-00874-2 · ExternalCitation · doi-reference
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
10.1038/s41591-023-02465-7 · ExternalCitation · doi-reference
FAM120A deficiency improves resistance to cisplatin in gastric cancer by promoting ferroptosis
10.1038/s42003-024-06097-6 · ExternalCitation · doi-reference
Loss of tight junction protein Claudin 18 promotes progressive neoplasia development in mouse stomach
10.1053/j.gastro.2018.08.041 · ExternalCitation · doi-reference
LEF1 suppresses ferroptosis in colorectal cancer cells by targeted promotion of SLC7A11 transcription
10.1096/fj.202502018r · ExternalCitation · doi-reference
Cysteine depletion induces pancreatic tumor ferroptosis in mice
10.1126/science.aaw9872 · ExternalCitation · doi-reference
Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development
10.1158/1078-0432.ccr-08-1547 · ExternalCitation · doi-reference
